Role of the Systemic Immune-Inflammation Index in Patients with Metastatic Renal Cell Carcinoma Treated with First-Line Ipilimumab plus Nivolumab

Stuhler, Viktoria; Herrmann, Lisa; Rausch, Steffen; Stenzl, Arnulf; Bedke, Jens

dc.contributor.author	Herrmann, Lisa
dc.contributor.author	Rausch, Steffen
dc.contributor.author	Stenzl, Arnulf
dc.contributor.author	Bedke, Jens
dc.contributor.author	Stühler, Viktoria
dc.date.accessioned	2022-11-07T10:06:39Z
dc.date.available	2022-11-07T10:06:39Z
dc.date.issued	2022
dc.identifier.issn	2072-6694
dc.identifier.uri	http://hdl.handle.net/10900/132845
dc.language.iso	en	de_DE
dc.publisher	Mdpi	de_DE
dc.relation.uri	http://dx.doi.org/10.3390/cancers14122972	de_DE
dc.subject.ddc	610	de_DE
dc.title	Role of the Systemic Immune-Inflammation Index in Patients with Metastatic Renal Cell Carcinoma Treated with First-Line Ipilimumab plus Nivolumab	de_DE
dc.type	Article	de_DE
utue.quellen.id	20220728000000_00576
utue.personen.roh	Stuhler, Viktoria
utue.personen.roh	Herrmann, Lisa
utue.personen.roh	Rausch, Steffen
utue.personen.roh	Stenzl, Arnulf
utue.personen.roh	Bedke, Jens
dcterms.isPartOf.ZSTitelID	Cancers	de_DE
dcterms.isPartOf.ZS-Issue	Article 2972	de_DE
dcterms.isPartOf.ZS-Volume	14 (12)	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE